Skip to main content
Journal of Pain Research logoLink to Journal of Pain Research
. 2026 Apr 15;19:591459. doi: 10.2147/JPR.S591459

Comparative Efficacy of Canggui Tanxue Acupuncture Combined with Scapular Stabilization Training versus Scapular Stabilization Training Alone for Rotator Cuff Injury: A Retrospective Cohort Study

Yining Geng 1,*, Manping Song 1,*, Bing Huang 1,*, Ru Lin 1, Shiwen Wu 2, An Lin 2, Xiaolin Wang 3,
PMCID: PMC13092458  PMID: 42017148

Abstract

Aim

To evaluate the clinical efficacy of combining Canggui Tanxue acupunc-ture combined with scapular stabilization training (SST) versus SST alone for mild-to-moderate rotator cuff injuries (RCI) in a real-world clinical setting.

Methods

This retrospective cohort study analyzed 160 patients with mild-to-moderate RCI treated at Department of Acupuncture, Hainan General Hospital between January 2024 and June 2025. Patients were categorized into two groups based on treatment received: SST alone (Control group, n = 80) and SST plus Canggui Tanxue acupuncture (Combination group, n = 80). Primary outcomes included shoulder function (American Shoulder and Elbow Surgeons [ASES] score), pain intensity (Visual Analog Scale [VAS]), active range of motion (ROM), quality of life (Short Form-36 [SF-36]), and clinical efficacy rates. Data were extracted from electronic medical records.

Results

The Combination group demonstrated significantly superior outcomes compared to the Control group: higher ASES scores (93.31 ± 9.09 vs. 81.42 ± 8.45, P < 0.001), lower VAS scores (2.09 ± 0.48 vs. 3.52 ± 0.93, P < 0.001), greater ROM improvements (e.g. external rotation: 80.40 ± 8.22 vs. 65.59 ± 7.86, P < 0.001), and higher SF-36 scores (80.51 ± 8.48 vs. 65.44 ± 8.29, P < 0.001). Clinical efficacy rates were superior in the Combina-tion group (excellent: 76.25% vs. 47.50%; total efficacy: 93.75% vs. 77.50%, P < 0.001). Effect sizes were large for ASES (Cohen’s d=1.42) and VAS (d=−1.89). The number needed to treat (NNT) for achieving excellent efficacy was 3.48.

Conclusions and Implications

The study demonstrates that integrating Canggui Tanxue acupuncture with SST yields clinically meaningful improvements in shoulder function, pain relief, and quality of life for mild-to-moderate RCI patients, surpassing SST alone. These findings support the adoption of this combined approach in routine clinical practice, particularly given its high efficacy (NNT = 3.48) and large effect sizes.

Keywords: rotator cuff injury, acupuncture, Canggui Tanxue, scapular stabilization, real-world evidence, retrospective cohort study

Introduction

Rotator cuff injury (RCI), characterized by structural damage to the supraspinatus, infraspinatus, teres minor, and subscapularis tendons, is among the most prevalent musculoskeletal disorders worldwide and a major contributor to chronic shoulder pain cases. Its primary etiology involves mechanical stressors (eg. repetitive overhead activity, trauma, or age-related degeneration), resulting in tendon inflammation, microtears, and functional impairment.1 Clinically, RCI manifests as debilitating pain, restricted range of motion (ROM), and compromised activities of daily living (ADLs), significantly reducing quality of life and imposing substantial socioeconomic burdens.2 Without timely intervention, RCI may progress to irreversible complications, including muscle atrophy, fatty infiltration, and glenohumeral joint instability, often necessitating surgical management.

Current therapeutic strategies encompass conservative and surgical approaches. While arthroscopic repair demonstrates efficacy for severe tears, its inherent risks include surgical complications, prolonged rehabilitation, and variable functional outcomes.3,4 Consequently, non-surgical modalities remain first-line for mild-to-moderate RCI, focusing on pain control, functional restoration, and prevention of disease progression. Among these, scapular stabilization training (SST) has emerged as a cornerstone intervention by targeting scapulothoracic dyskinesia—a key biomechanical factor in RCI pathogenesis. SST enhances neuromuscular control, optimizes shoulder kinematics, and promotes tendon healing through structured exercises that facilitate scapular repositioning and muscle coordination.5 Nevertheless, SST monotherapy exhibits limitations, including slow symptomatic relief, suboptimal pain modulation, and plateaued efficacy in subsets of patients, underscoring the need for adjunctive therapies.

Complementary to biomechanical approaches, Canggui Tanxue acupuncture—a specialized technique involving multi-directional, layered needle stimulation—offers a neurophysiological pathway to pain management and tissue repair.6 By targeting acupoints such as Jianyu (LI15) and Ashi points, this method is proposed to modulate nociceptive signaling, resolve local qi-blood stasis, and improve microcirculation, synergistically addressing inflammatory and functional aspects of RCI. From a Traditional Chinese Medicine perspective, the Canggui Tanxue acupuncture deeply penetrates fascial layers to resolve local Qi and blood stasis. Neurophysiologically, this multi-directional and layered mechanical stimulation disrupts fibrotic adhesions and modulates peripheral nociceptors, thereby reducing central sensitization and optimizing local microcirculation.7 Although acupuncture is empirically integrated into some rehabilitation protocols, robust evidence evaluating its combination with evidence-based SST for RCI remains limited.

Given the multifactorial nature of RCI—encompassing biomechanical dysfunction, peripheral sensitization, and chronic pain pathways—a combinatorial strategy targeting both structural and neurophysiological dimensions holds theoretical promise. However, the clinical synergy between SST and Canggui Tanxue acupuncture remains underexplored, with limited high-quality trials quantifying their integrated efficacy. This knowledge gap impedes the optimization of non-surgical RCI management algorithms. While randomized trials are ideal, real-world evidence from clinical practice is critical for validating treatment effectiveness. This retrospective cohort study leverages existing clinical data to compare outcomes between SST monotherapy and SST combined with Canggui Tanxue acupuncture, providing pragmatic insights into potential synergistic effects. We hypothesize that the combined protocol will yield superior improvements in pain relief, functional recovery, and quality of life by concurrently modulating scapulothoracic biomechanics and pain modulation pathways. The findings aim to inform evidence-based clinical decision-making, offering a safer, more effective conservative strategy for RCI patients.

Materials and Methods

Study Design and Participants

Retrospective cohort study using electronic health records from the Depart-ment of Acupuncture, Hainan General Hospital, Hainan Medical University (January 2024–June 2025). A total of 160 eligible patients meeting inclusion cri-teria were enrolled and assigned based on actual treatment received into two groups: Control group (SST alone, n = 80) or Combination group (SST plus Canggui Tanxue acupuncture, n = 80). As a retrospective cohort study, patients were not randomized. Treatment allocation was based on shared clinical decision-making, patient preference regarding the acceptance of acupuncture, and the availability of acupuncturists at the time of consultation. Ethical approval was granted by the Insti-tutional Review Board of Hainan General Hospital, Hainan Medical University (Approval No. YL-2025-03). All procedures adhered to the Declaration of Hel-sinki.

Inclusion and Exclusion Criteria

Inclusion Criteria

(1) Diagnosis of RCI per standard Western medical crite-ria; (2) Grade I or II RCI; (3) Age 25–60 years; (4) Symptom duration > 7 days; (5) Complete clinical data; (6) Voluntary participation with informed consent.

Exclusion Criteria

(1) Concurrent shoulder pathologies (eg., dislocation, fracture); (2) Massive rotator cuff tear; (3) Hepatic or renal dysfunction; (4) Psychiatric disorders or cognitive impairment; (5) Prior surgical intervention for RCI; (6) Concurrent malignancy or participation in other trials; (7) Inability to cooperate with treatment.

Treatment Methods

Control Group

Patients received SST twice daily for 6 weeks. To ensure both professional guidance and adequate treatment frequency, this regimen consisted of one supervised session conducted in the hospital rehabilitation center and one prescribed home-based exercise session. The supervised SST protocol included the following: (1) Scapular Facilitation Training (10 min/session): The therapist, positioned beside the seated patient, elevated the scapular girdle while adducting the scapula and externally mobilizing the pectoralis major. Then reversed the motion (abduction/upward ro-tation of scapula with adduction/depression of pectoralis major). (2) Scapular Control Training (10 min/session): Patients maintained a seated position, using the Bobath handshake grip under therapist guidance to ensure correct gleno-humeral alignment. (3) Trunk Anti-gravity Extension Training (10 min/session): Patients maintained a seated position and is instructed by the therapist to perform scapular adduction while the head is extended against gravity.

Combination Group

Patients received SST (identical to the Control Group) plus Canggui Tanxue acupuncture. The acupuncture sessions were administered on the same day, immediately prior to the supervised hospital SST session. This specific sequence was designed to maximize initial pain relief and fascial release, thereby facilitating better gleno-humeral alignment and biomechanical execution during the subsequent stabilization exercises. The acupuncture protocol was as follows: (1) Positioning: Lateral decubitus (healthy side down) or seated based on tear location. (2) Acupoints: Jianyu (LI15), Jianqian (Extra), Jianhou (SI10), Ashi points. (3) Needling: 0.30 mm × 40 mm filiform needles inserted perpendicularly to the Di (Earth) region depth; withdrawn to Tian (Heaven) region upon Deqi. (4) Technique: Oblique needling (45°) per-formed in multiple directions (superior, inferior, left, right) and depths (Tian, Ren, Di regions), seeking Deqi each time. (5) Retention: Needles retained for 30 minutes per session. (6) Frequency: Twice per session, five times weekly for 6 weeks.

Outcome Measures

  1. Shoulder function: American Shoulder and Elbow Surgeons (ASES) score (0–100, lower = worse function).8

  2. Pain intensity: Visual Analog Scale (VAS) (0–10 cm, lower = less pain).9

  3. Active myofascial trigger points (MTrPs): Counted via systematic palpation by trained clinicians.10

  4. Active range of motion (ROM): Assessed using a universal goniometer for external rotation, internal rotation, anterior flexion, and posterior extension (mean of 3 measurements).11

  5. Quality of life: 36-Item Short-Form Health Survey (SF-36) (0–100, lower=worse quality of life).12

  6. Clinical Efficacy Rate: Classified by VAS improvement: Cured (≥ 90%), Markedly Effective (60–89%), Effective (30–59%), Ineffective (< 30%). Excellent Rate = (Cured + Markedly Effective)/Total × 100%. Total Efficacy Rate = (Cured + Markedly Effective + Effective)/Total × 100%.6

All outcome assessments were conducted immediately following the 6-week intervention period. Due to the retrospective nature of the database, standardized long-term follow-up data beyond 6 weeks were not available. Outcome assessments (including ASES, VAS, ROM, MTrPs, and SF-36) were performed by independent blinded assessors who were not involved in treatment delivery and were unaware of group allocation. To maintain blinding, all patient identifiers and treatment codes were concealed during data collection and analysis.

Statistical Analysis

Baseline-adjusted analyses used ANCOVA with baseline scores as covariates. False discovery rate (FDR) correction was applied for multiple comparisons (q<0.05 considered significant). All statistical analyses were performed using R software (version 4.2.2) and SAS statistical software (version 9.4; SAS Institute Inc., Cary, NC, USA). Categorical variables were presented as frequencies (per-centages), and group comparisons were conducted using the chi-square test. Normally distributed continuous variables were expressed as mean ± standard deviation (SD), and group comparisons were performed using analysis of vari-ance (ANOVA). Non-normally distributed continuous variables were reported as median (interquartile range [IQR]), and group comparisons were analyzed using the Wilcoxon rank-sum test. Pearson correlation analysis (for normally distribut-ed data) or Spearman correlation analysis (for non-normally distributed data) was employed to explore the associations between demographic characteristics and study outcomes.

Advanced analyses: (1) Stratified analysis to evaluate efficacy across sub-groups; (2) Multiple linear regression and binary logistic regression models to assess the effects of interventions and clinical indicators on clinical outcomes and improvement effects; (3) Receiver operating characteristic (ROC) curve, decision curve analysis (DCA), and Kolmogorov–Smirnov (KS) curve to evaluate the pre-dictive performance of various indicators for treatment excellent rate and overall response rate; (4) Least absolute shrinkage and selection operator (LASSO) re-gression to screen key predictive variables and construct a nomogram prediction model.All hypothesis tests were two-sided, and a P-value < 0.05 was considered statistically significant.

Furthermore, to validate the methodological strength of this retrospective cohort, a post-hoc power analysis was conducted using the pwr package in R. For the primary continuous outcomes, utilizing an observed large effect size (Cohen’s d > 1.4), a sample size of 80 patients per group, and a two-tailed significance level of 0.05, the statistical power was calculated to exceed 0.99. This confirms that the current sample size was highly sufficient to detect the observed intervention effects.

Results

Patient Characteristics

A total of 160 RCI patients were divided into the Control group (SST alone, n = 80) and Combination group (SST + Canggui Tanxue acupuncture, n = 80). Baseline characteristics were comparable between groups (all P > 0.05). The Control group comprised 48 males (60.00%) and 32 females (40.00%), with a mean age of 48.55 ± 7.21 years; the Combination group included 51 males (63.75%) and 29 females (36.25%), mean age 48.41 ± 7.30 years. Disease dura-tion was comparable (Control: 4.90 ± 0.75 months; Combination: 4.84 ± 0.71 months). Regarding injury distribution, the Control group presented with 37 left-sided injuries, 36 right-sided injuries, and 7 bilateral injuries, whereas the Combination group had 36 left-sided, 39 right-sided, and 5 bilateral injuries. Sta-tistical analysis confirmed no significant differences in any baseline characteris-tics between groups (P > 0.05), as detailed in Table 1.

Table 1.

Patient Characteristics

[ALL]
n = 160
Combination
Group n = 80
Control
Group n = 80
P value
Age 49.33 (6.62) 50.01 (6.53) 48.64 (6.68) 0.19
Gender: 0.745
Female 61 (38.12%) 29 (36.25%) 32 (40.00%)
Male 99 (61.88%) 51 (63.75%) 48 (60.00%)
Injury Site: 0.426
Both shoulders 10 (6.25%) 3 (3.75%) 7 (8.75%)
Left shoulder 72 (45.00%) 37 (46.25%) 35 (43.75%)
Right shoulder 78 (48.75%) 40 (50.00%) 38 (47.50%)
Disease Duration (Months): 0.159
3 4 (2.50%) 3 (3.75%) 1 (1.25%)
4 43 (26.88%) 21 (26.25%) 22 (27.50%)
5 78 (48.75%) 33 (41.25%) 45 (56.25%)
6 32 (20.00%) 21 (26.25%) 11 (13.75%)
7 3 (1.88%) 2 (2.50%) 1 (1.25%)

Primary Outcomes

After baseline adjustment, the Combination group showed superior outcomes across all primary endpoints. Shoulder function assessed by ASES scores improved markedly in the Combination group (93.56 ± 8.69) compared to Controls (82.14 ± 9.11, P < 0.001), paralleled by greater pain reduction in VAS scores (2.09 ± 0.48 vs. 3.52 ± 0.93, P < 0.001) and fewer active myofascial trigger points (MTrPs: 2.95 ± 0.57 vs. 4.00 ± 0.80, P < 0.001). ROM measurements revealed substantial gains in the Combination group: external rotation increased to 80.40 ± 8.22 vs. 65.59 ± 7.86 in Controls (P < 0.001), internal rotation to 59.26 ± 6.82 vs. 48.33 ± 5.56 (P < 0.001), anterior flexion to 176.41 ± 19.25 vs. 150.65 ± 18.98 (P < 0.001), and extension to 58.52 ± 6.18 versus 48.78 ± 5.39 (P < 0.001). SF-36 scores also improved more significantly in the Combination group (80.51 ± 8.48 vs. 65.44 ± 8.29, P < 0.001). Critically, clinical efficacy rates favored the Combination group, with a 76.25% excellent rate (vs. 47.50% in Controls) and 93.75% total efficacy rate (vs. 77.50%, P < 0.001) (Table 2 and Figure 1).

Table 2.

Primary Outcomes

[ALL]
n = 160
Combination
Group n = 80
Control
Group n = 80
P value
ASES_before 64.40 (6.52) 64.33 (6.98) 64.47 (6.07) 0.885
ASES_after 87.85 (10.56) 93.56 (8.69) 82.14 (9.11) <0.001
VAS_before 7.50 [6.00;9.00] 8.00 [6.00;10.00] 7.00 [6.00;9.00] 0.168
VAS_after 3.00 [2.00;4.00] 2.00 [2.00;3.00] 4.00 [3.00;4.00] <0.001
MTrPs_before 6.00 [5.00;7.00] 6.00 [5.00;7.00] 6.00 [5.00;7.00] 0.699
MTrPs_after 3.00 [3.00;4.00] 3.00 [3.00;3.00] 4.00 [4.00;5.00] <0.001
ROM_ER_before 51.19 (5.60) 51.49 (5.42) 50.89 (5.79) 0.499
ROM_ER_after 72.11 (10.39) 79.16 (7.56) 65.06 (7.71) <0.001
ROM_IR_before 41.62 (4.46) 41.15 (4.31) 42.10 (4.58) 0.179
ROM_IR_after 53.19 (7.98) 58.50 (6.47) 47.88 (5.41) <0.001
ROM_FF_before 123.77 (15.11) 123.36 (15.45) 124.17 (14.86) 0.735
ROM_FF_after 164.69 (24.27) 178.94 (19.85) 150.45 (19.51) <0.001
ROM_Ext_before 27.80 (4.27) 27.73 (4.15) 27.88 (4.42) 0.825
ROM_Ext_after 54.09 (7.17) 58.99 (5.86) 49.20 (4.55) <0.001
SF36_before 52.54 (5.83) 53.16 (5.85) 51.91 (5.77) 0.176
SF36_after 72.93 (11.15) 80.42 (8.23) 65.44 (8.29) <0.001
Efficacy: <0.001
Cured 41 (25.62%) 17 (21.25%) 24 (30.00%)
Effective 34 (21.25%) 12 (15.00%) 22 (27.50%)
Ineffective 21 (13.12%) 6 (7.50%) 15 (18.75%)
Markedly effective 64 (40.00%) 45 (56.25%) 19 (23.75%)
Excellent Rate: 0.003
0 55 (34.38%) 18 (22.50%) 37 (46.25%)
1 105 (65.62%) 62 (77.50%) 43 (53.75%)
Total Efficacy: 0.061
0 21 (13.12%) 6 (7.50%) 15 (18.75%)
1 139 (86.88%) 74 (92.50%) 65 (81.25%)

Figure 1.

Three graphs: radar chart, correlation heatmap and grouped bar chart on treatment outcome measures. 1. Is the input legible and have you properly understood the image? yes The image A showing a radar chart titled with axis labels ASES, VAS, MTrPs, ROM dash ER, ROM dash IR, ROM dash FF, ROM dash Ext and SF36. Radial scale labeled 0, 100, 200. Legend entries: Both shoulders after; Both shoulders before; Female after; Female before; Left shoulder after; Left shoulder before; Male after; Male before; Right shoulder after; Right shoulder before. The plotted polygons show ROM dash FF as the largest spoke for all groups, with after traces generally farther from the center than before traces on ASES, SF36, ROM dash ER, ROM dash IR, ROM dash FF and ROM dash Ext, while VAS and MTrPs spokes are shorter after than before. The image B showing a correlation heatmap with a vertical legend titled Correlation Coefficient ranging from negative 1.0 to 1.0. Column labels: Age, Gender, Injury site, Disease duration. Row labels grouped by measure and time: ASES dash before, ASES dash after; VAS dash before, VAS dash after; MTrPs dash before, MTrPs dash after; ROM dash ER dash before, ROM dash ER dash after; ROM dash IR dash before, ROM dash IR dash after; ROM dash FF dash before, ROM dash FF dash after; ROM dash Ext dash before, ROM dash Ext dash after; SF36 dash before, SF36 dash after; Efficacy; Excellent rate; Total efficacy. Most cells appear near the midrange of the scale with small positive and negative values. The image C showing a grouped bar chart with y axis label Value and range 0 to 250 with ticks at 0, 50, 100, 150, 200, 250. X axis categories: ASES, VAS, MTrPs, ROM dash ER, ROM dash IR, ROM dash FF, ROM dash Ext, SF36. Legend: Combination after, Combination before, Control after, Control before. Bars include overlaid dot markers. Across categories, Combination after bars are generally highest for ASES, ROM dash ER, ROM dash IR, ROM dash FF, ROM dash Ext and SF36, while VAS and MTrPs are lower after than before in both groups. ROM dash FF shows the tallest bars overall, reaching between 150 and 200 for Combination after, with other ROM measures and ASES and SF36 mostly between 50 and 120 and VAS and MTrPs near 0 to 10.

Multidimensional assessment of treatment outcomes. (A) Radar chart displaying changes in ASES, VAS, SF-36, MTrPs, and ROM parameters across injury site/gender subgroups; (B) Heatmap showing correlations between demographic factors and clinical indicators; (C) Intergroup comparison of assessment metrics pre- and post-intervention.

Abbreviations: ASES, American Shoulder and Elbow Surgeons score; VAS, Visual Analog Scale; MTrPs, Myofascial Trigger Points; ROM, Range of Motion; SF-36, 36-Item Short-Form Health Survey.

Correlation and Regression Analyses

Robust correlations were observed between functional recovery and pain modulation. Post-intervention ROM parameters strongly correlated with ASES/SF-36 scores (r > 0.7) and inversely correlated with VAS/MTrPs (r < −0.6; all P < 0.001). Excellent efficacy rates showed negative associations with residual MTrPs (r = −0.53) and VAS (r = −0.61) (Figure 2). Linear regression quantified the treatment effect: the combined protocol independently improved ASES (β = 11.334, 95% CI: 8.508–14.160) and reduced VAS (β = −1.443, 95% CI: −1.686 to −1.200; both P < 0.001), with ROM-Extension (β = 9.767) and ROM-Internal Rotation (β = 10.593) identified as key functional drivers (Figure 3). Predictive modeling reinforced these findings: ROM-Extension (AUC = 0.722) and MTrP reduction (AUC = 0.697) emerged as top predictors for excellent efficacy, while the comprehensive model (ALL) achieved optimal clinical utility (AUC = 0.740; net benefit: 0.4–0.8 across risk thresholds; Figures 4–6). LASSO-based nomograms further validated ROM-Extension (OR = 1.091) and ROM-Internal Rotation (OR = 1.062) as primary determinants of excellent outcomes (both P ≤ 0.001; Figures 7–9).

Figure 2.

Heatmap of Correlation matrix of clinical indicators with rows and columns ASES, VAS, MTrPs, ROM ER, ROM IR, ROM FF, ROM Ext, SF36; cell numbers present. The image A showing two correlation heatmaps and a central connection diagram. Text at top right: Before. Text at bottom center: After. Left side legend text: Correlation Coefficient1 with scale labeled 1.0, 0.5, 0.0, negative 0.5, negative 1.0. Correlation Coefficient2 with categories less than negative 0.2 and negative 0.2 to 0.4. Line legend: Negative, Positive. Significance legend: P less than 0.05, P greater than 0.05. After heatmap (lower left triangle): axes list ASES, VAS, MTrPs, ROM ER, ROM IR, ROM FF, ROM Ext, SF36. Cells contain square markers and many cells contain three asterisks. Before heatmap (upper right triangle): axes list ASES, VAS, MTrPs, ROM ER, ROM IR, ROM FF, ROM Ext, SF36. Cells contain square markers; some contain a single asterisk. Center diagram: two bold labels, Excellent Rate and Total Efficacy, each connected by multiple dashed lines to small circular points aligned with the variable labels ASES, VAS, MTrPs, ROM ER, ROM IR, ROM FF, ROM Ext, SF36.

Correlation matrix of clinical indicators. The lower triangle presents the post-intervention associations between functional and pain metrics, while the upper triangle displays the pre-intervention baseline associations. Color intensity reflects the strength of the correlation (red = positive, blue = negative). Statistical significance is denoted as: *P<0.05; ***P<0.001.

Figure 3.

The image A showing a forest plot of linear regression coefficients with 95 percent confidence intervals. Left table headers: Outcome; beta left parenthesis 95 percent confidence interval right parenthesis. Rows: ASES 11.334 left parenthesis 8.508 to 14.160 right parenthesis. VAS minus 1.443 left parenthesis minus 1.686 to minus 1.200 right parenthesis. MTrPs minus 1.247 left parenthesis minus 1.477 to minus 1.017 right parenthesis. ROM ER 14.064 left parenthesis 11.642 to 16.487 right parenthesis. ROM IR 10.593 left parenthesis 8.696 to 12.490 right parenthesis. ROM FF 28.187 left parenthesis 21.938 to 34.435 right parenthesis. ROM Ext 9.767 left parenthesis 8.104 to 11.431 right parenthesis. SF36 14.880 left parenthesis 12.268 to 17.493 right parenthesis. Excellent rate 0.248 left parenthesis 0.103 to 0.393 right parenthesis. Total efficacy 0.124 left parenthesis 0.018 to 0.230 right parenthesis. Central graph x axis label: (unclear). Unit: (unclear). X axis range: minus 5 to 30 with ticks at minus 5, 0, 5, 10, 15, 20, 25, 30. A vertical solid line at 0 and a vertical dashed line at 5. Bottom labels: Anti effect on left, Pro effect on right. Right table headers: SE; P Value. Values by row: 1.431 and less than 0.001; 0.123 and less than 0.001; 0.117 and less than 0.001; 1.226 and less than 0.001; 0.960 and less than 0.001; 3.163 and less than 0.001; 0.842 and less than 0.001; 1.323 and less than 0.001; 0.073 and less than 0.001; 0.054 and less than 0.05. The detailed data points are as follows: - For outcome ASES, beta was 11.334, 95% CI lower was 8.508, 95% CI upper was 14.160, SE was 1.431 and P Value was less than 0.001. - For outcome VAS, beta was minus 1.443, 95% CI lower was minus 1.686, 95% CI upper was minus 1.200, SE was 0.123 and P Value was less than 0.001. - For outcome MTrPs, beta was minus 1.247, 95% CI lower was minus 1.477, 95% CI upper was minus 1.017, SE was 0.117 and P Value was less than 0.001. - For outcome ROM ER, beta was 14.064, 95% CI lower was 11.642, 95% CI upper was 16.487, SE was 1.226 and P Value was less than 0.001. - For outcome ROM IR, beta was 10.593, 95% CI lower was 8.696, 95% CI upper was 12.490, SE was 0.960 and P Value was less than 0.001. - For outcome ROM FF, beta was 28.187, 95% CI lower was 21.938, 95% CI upper was 34.435, SE was 3.163 and P Value was less than 0.001. - For outcome ROM Ext, beta was 9.767, 95% CI lower was 8.104, 95% CI upper was 11.431, SE was 0.842 and P Value was less than 0.001. - For outcome SF36, beta was 14.880, 95% CI lower was 12.268, 95% CI upper was 17.493, SE was 1.323 and P Value was less than 0.001. - For outcome Excellent rate, beta was 0.248, 95% CI lower was 0.103, 95% CI upper was 0.393, SE was 0.073 and P Value was less than 0.001. - For outcome Total efficacy, beta was 0.124, 95% CI lower was 0.018, 95% CI upper was 0.230, SE was 0.054 and P Value was less than 0.05.

Forest plot of linear regression coefficients (β) with 95% confidence intervals (CIs). The plot demonstrates the independent treatment effects of the combined protocol on functional outcomes (ASES, SF-36), pain metrics (VAS, MTrPs), ROM parameters, and overall clinical efficacy, adjusting for baseline covariates. The dashed vertical line indicates a null effect (β = 0).

Figure 4.

Two multi-line graphs of receiver operating characteristic curves for excellent and total efficacy rate. The image A showing a multi-line graph with legend entries ASES, VAS, MTrPs, ROM-ER, ROM-IR, ROM-FF, ROM-Ext, SF-36, ALL, None. The purpose text is not shown in this sub-image. The x-axis label is High Risk Threshold (unit unclear), with tick labels 0.0, 0.2, 0.4, 0.6, 0.8, 1.0. A second x-axis label is Cost:Benefit Ratio (unit unclear), with tick labels 1:100, 1:4, 2:3, 3:2, 4:1, 100:1. The y-axis label is Standardized Net Benefit (unit unclear), with tick labels 0.0, 0.2, 0.4, 0.6, 0.8, 1.0. The plotted elements are multiple solid lines, each corresponding to one legend entry; line-style differences beyond solid lines are not indicated. Numeric data extraction: None line is a horizontal line at y equals 0.0 across x from 0.0 to 1.0. Other curves begin near y equals 1.0 at x equals 0.0 and generally decline toward y near 0.0 by x near 1.0; exact coordinate pairs for these curves are not readable due to dense overlap. Relative comparison: the curve labeled ALL stays above many other curves through mid-range thresholds and remains positive longer before approaching y near 0.0 close to x near 1.0. The image B showing a multi-line graph with legend entries ASES, VAS, MTrPs, ROM-ER, ROM-IR, ROM-FF, ROM-Ext, SF-36, ALL, None. The purpose text is not shown in this sub-image. The x-axis label is High Risk Threshold (unit unclear), with tick labels 0.0, 0.2, 0.4, 0.6, 0.8, 1.0. A second x-axis label is Cost:Benefit Ratio (unit unclear), with tick labels 1:100, 1:4, 2:3, 3:2, 4:1, 100:1. The y-axis label is Standardized Net Benefit (unit unclear), with tick labels 0.0, 0.2, 0.4, 0.6, 0.8, 1.0. The plotted elements are multiple solid lines, each corresponding to one legend entry; line-style differences beyond solid lines are not indicated. Numeric data extraction: None line is a horizontal line at y equals 0.0 across x from 0.0 to 1.0. Other curves stay near y close to 1.0 from x equals 0.0 through roughly x between 0.4 and 0.7, then drop steeply after x around 0.7 to 0.9 toward y near 0.0 by x near 1.0; exact coordinate pairs for these curves are not readable due to dense overlap. Relative comparison: the curve labeled ALL remains among the higher net-benefit curves across much of the threshold range before converging toward y near 0.0 near x near 1.0.

Receiver operating characteristic (ROC) curves evaluating the predictive performance of clinical indicators for (A) excellent efficacy rate and (B) total efficacy rate. Area under the curve (AUC) values with 95% CIs are presented for individual post-intervention parameters. The comprehensive prediction model (ALL) specifically includes ASES_after + VAS_after + ROM_Ext_after, demonstrating the highest diagnostic accuracy.

Figure 5.

Two receiver operating characteristic plots for excellent efficacy rate and total efficacy rate models. X-axis label: 1 minus Specificity (unit not shown), range 0.00 to 1.00. Y-axis label: Sensitivity (unit not shown), range 0.00 to 1.00. A diagonal reference line runs from (0.00, 0.00) to (1.00, 1.00). Multiple step-like curves are shown with legend area under the curve values: 0.686, 0.698, 0.653, 0.673, 0.758, 0.673, 0.667, 0.699, 0.702. Model text includes: Model: ALL, area under the curve 0.704 (0.656 to 0.751), P less than 0.001; Model: SF36, area under the curve 0.653 (0.576 to 0.730), P less than 0.001; Model: ROMF, area under the curve 0.665 (0.591 to 0.741), P less than 0.001; Model: ROMER, area under the curve 0.666 (0.578 to 0.755), P less than 0.001; Model: MITP, area under the curve 0.697 (0.614 to 0.781), P less than 0.001; Model: VAS, area under the curve 0.684 (0.595 to 0.773), P less than 0.001. The image B showing a receiver operating characteristic plot. X-axis label: 1 minus Specificity (unit not shown), range 0.00 to 1.00. Y-axis label: Sensitivity (unit not shown), range 0.00 to 1.00. A diagonal reference line runs from (0.00, 0.00) to (1.00, 1.00). Multiple step-like curves are shown with legend area under the curve values: 0.855, 0.875, 0.864, 0.877, 0.887, 0.892, 0.888, 0.886, 0.880. Model text includes: Model: ALL, area under the curve 0.860 (0.819 to 0.883), P less than 0.001; Model: SF36, area under the curve 0.809 (0.759 to 0.861), P less than 0.001; Model: ROMF, area under the curve 0.839 (0.802 to 0.880), P less than 0.001; Model: ROMER, area under the curve 0.861 (0.818 to 0.904), P less than 0.001; Model: ROM_IR, area under the curve 0.867 (0.838 to 0.896), P less than 0.001; Model: MITP, area under the curve 0.874 (0.853 to 0.895), P less than 0.001; Model: VAS, area under the curve 0.814 (0.761 to 0.867), P less than 0.001.

Decision curve analysis (DCA) evaluating the clinical utility of the predictive models across various risk thresholds for (A) excellent efficacy rate and (B) total efficacy rate. The standardized net benefit (Y-axis, range 0–1.0) is plotted against the threshold probability (X-axis, high-risk threshold from 0–1.0). Higher net benefit values indicate superior clinical utility across different clinical decision-making scenarios. The comprehensive model (ALL: ASES_after + VAS_after + ROM_Ext_after) consistently demonstrates the highest net benefit.

Figure 6.

Two sets of line graphs for Outcome:Excellent Rate and Outcome:Total Efficacy KS curves. The image A showing Outcome:Excellent Rate with nine line graphs titled MTrPs, ASES, VAS, SF36, ROM-ER, ROM-Ext, ROM-FF, ROM-IR and ALL. Each graph has x-axis label Cutoff(c) (unit unclear) and y-axis label Value (unit unclear). Legends list TPR, FPR and KS (numeric value shown but unclear). MTrPs: x-axis ticks 0.4, 0.6, 0.8, 1.0; y-axis ticks 0.0 to 1.0. ASES: x-axis ticks 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0; y-axis 0.0 to 1.0. VAS: x-axis ticks 0.4, 0.6, 0.8, 1.0; y-axis 0.0 to 1.0. SF36: x-axis ticks 0.4, 0.6, 0.8, 1.0; y-axis 0.0 to 1.0. ROM-ER: x-axis ticks 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0; y-axis 0.0 to 1.0. ROM-Ext: x-axis ticks 0.4, 0.6, 0.8, 1.0; y-axis 0.0 to 1.0. ROM-FF: x-axis ticks 0.4, 0.6, 0.8, 1.0; y-axis 0.0 to 1.0. ROM-IR: x-axis ticks 0.4, 0.6, 0.8, 1.0; y-axis 0.0 to 1.0. ALL: x-axis ticks 0.2, 0.4, 0.6, 0.8, 1.0; y-axis ticks 0.0 to 1.0. The image B showing Outcome:Total Efficacy with nine line graphs titled MTrPs, ASES, VAS, SF36, ROM-ER, ROM-Ext, ROM-FF, ROM-IR and ALL. Each graph has x-axis label Cutoff(c) (unit unclear) and y-axis label Value (unit unclear). Legends list TPR, FPR and KS (numeric value shown but unclear). MTrPs: x-axis ticks 0.6, 0.7, 0.8, 0.9, 1.0; y-axis 0.0 to 1.0. ASES: x-axis ticks 0.70, 0.75, 0.80, 0.85, 0.90, 0.95, 1.00; y-axis 0.0 to 1.0. VAS: x-axis ticks 0.8, 0.9, 1.0; y-axis 0.0 to 1.0. SF36: x-axis ticks 0.7, 0.8, 0.9, 1.0; y-axis 0.0 to 1.0. ROM-ER: x-axis ticks 0.7, 0.8, 0.9, 1.0; y-axis 0.0 to 1.0. ROM-Ext: x-axis ticks 0.8, 0.9, 1.0; y-axis 0.0 to 1.0. ROM-FF: x-axis ticks 0.8, 0.9, 1.0; y-axis 0.0 to 1.0. ROM-IR: x-axis ticks 0.8, 0.9, 1.0; y-axis 0.0 to 1.0. ALL: x-axis ticks 0.6, 0.7, 0.8, 0.9, 1.0; y-axis 0.0 to 1.0.

Kolmogorov–Smirnov (KS) curves displaying the distributions of the true positive rate (TPR) and false positive rate (FPR) for (A) excellent efficacy rate and (B) total efficacy rate predictions based on the comprehensive model (ALL: ASES_after + VAS_after + ROM_Ext_after). The TPR curve illustrates the rapid ascent with increasing predicted probability, indicating effective capture of high-probability positive cases. The FPR curve demonstrates a gradual increase, suggesting minimal misclassification of low-probability positive cases. The maximum vertical distance between the TPR and FPR curves relative to the diagonal represents the KS statistic value.

Figure 7.

Four line graphs for Least absolute shrinkage and selection operator regression variable selection outcomes. The image A) showing Outcome:Excellent Rate coefficient profile plot. Graph type: multi-line plot. X-axis label: Log Lambda (unit unclear), range negative 7 to negative 3. Y-axis label: Coefficients (unit unclear), range about negative 0.5 to positive 0.4. Curves: one rises from about negative 0.5 at Log Lambda negative 7 to 0 at about negative 3; two fall from about positive 0.3 at negative 7 to 0 at about negative 3; several stay near 0 and converge to 0 at about negative 3. The image B) showing Outcome:Total Efficacy coefficient profile plot. Graph type: multi-line plot. X-axis label: Log Lambda (unit unclear), range negative 7 to negative 3. Y-axis label: Coefficients (unit unclear), range about negative 0.7 to positive 0.2. One curve rises from about negative 0.7 at negative 7 to 0 at about negative 3; other curves start between about negative 0.1 and positive 0.15 and converge to 0 at about negative 3. The image C) showing 10-fold cross-validation curve plot for excellent rate. Graph type: point-and-error-bar curve. X-axis label: Log Lambda (unit unclear), range negative 7 to negative 3. Y-axis label: Binomial deviance (unit unclear), range about 1.30 to 1.52. Red points with vertical error bars decrease from about 1.44 at Log Lambda near negative 7 to about 1.34 at Log Lambda near negative 3. Two dotted vertical lines at about Log Lambda negative 4.6 and negative 3.8. The image D) showing 10-fold cross-validation curve plot for total efficacy. Graph type: point-and-error-bar curve. X-axis label: Log Lambda (unit unclear), range negative 7 to negative 3. Y-axis label: Binomial deviance (unit unclear), range about 0.25 to 0.45. Red points with vertical error bars decrease from about 0.39 at Log Lambda near negative 7 to about 0.30 at Log Lambda near negative 3. Two dotted vertical lines at about Log Lambda negative 4.1 and negative 3.6. Relationship across A to D: A and B show coefficient trajectories versus Log Lambda for two outcomes and C and D show binomial deviance versus Log Lambda with dotted-line selections for the corresponding outcomes.

Least absolute shrinkage and selection operator (LASSO) regression analysis for variable selection. (Ai) Coefficient profile plot for predicting the excellent efficacy rate. The trajectory of each predictor’s coefficient is shown as log(λ) changes. (Bi) Coefficient profile plot for predicting the total efficacy rate. (Aii and Bii) 10-fold cross-validation curve plots used to select the optimal lambda (λ) for the excellent rate (Aii) and total efficacy (Bii) prediction models. The vertical axis represents the model error (binomial deviance), and the horizontal axis represents log(λ). The two dotted vertical lines indicate the optimal values: the left dotted line represents the λ value that yields the minimum criteria (λmin), and the right dotted line represents the λ value that yields the 1 standard error of the minimum criteria (λ1se). Key predictive variables were selected based on the optimal λmin values to construct the nomogram models.

Figure 8.

Two nomogram plots predicting excellent rate and total efficacy, with example scoring and probability readout. Top scale: Points (no unit), 0 to 100. Predictors listed: Injury site, Gender, Age, SF36, ROM Ext, ROM FF, ROM IR, ROM ER, MTrPs, VAS, ASES, then Total points and Pr() (no unit). Injury site has categories Right shoulder, Left shoulder, Both shoulders. Gender has Male and Female. Total points axis (no unit) ranges 400 to 600. Pr() axis (no unit) ranges 0.2 to 0.96. Red example markers show Total points equals 433 and Pr() equals 0.343. B) The image B showing “Outcome:Total Efficacy” and “Prediction Nomogram”. Top scale: Points (no unit), 0 to 100. Predictors listed: Gender, Age, SF36, ROM Ext, ROM IR, ROM ER, MTrPs, ASES, then Total points and Pr() (no unit). Gender has Male and Female. Total points axis (no unit) ranges 250 to 450. Pr() axis (no unit) ranges 0.3 to 0.985. Red example markers show Total points equals 346 and Pr() equals 0.819.

Nomogram prediction models for estimating clinical outcomes. (A) Nomogram predicting the probability of achieving an excellent efficacy rate; (B) Nomogram predicting the probability of achieving total efficacy. Segment lengths on the respective scales indicate the relative contribution weights of each selected predictor. The red visual elements illustrate how to use the nomogram for a hypothetical patient example. The red dots on each variable axis represent the patient’s specific clinical values. The red vertical dotted lines map these individual values upwards to the “Points” axis (top scale) to assign a specific score for each variable. The red diamond on the “Total points” axis represents the sum of all individual scores for this patient (e.g., 433 in (A), and 346 in (B)). The solid red downward arrow projects this total score onto the bottom “Pr()” axis to reveal the final predicted probability of the clinical outcome (e.g., 0.343 in (A), and 0.819 in (B).

Figure 9.

Two forest plots comparing odds ratios for excellent rate and total efficacy across clinical indicators. Subgroup rows: ASES, VAS, MTrPs, ROM ER, ROM IR, ROM FF, ROM Ext, SF36. Excellent Rate odds ratio (95 percent confidence interval): ASES 1.015 (0.983 to 1.049); VAS 0.727 (0.528 to 1.002); MTrPs 0.607 (0.420 to 0.877); ROM ER 1.047 (1.012 to 1.084); ROM IR 1.062 (1.015 to 1.112); ROM FF 1.010 (0.996 to 1.024); ROM Ext 1.091 (1.035 to 1.150); SF36 1.024 (0.993 to 1.056). Total Efficacy odds ratio (95 percent confidence interval): ASES 0.998 (0.954 to 1.045); VAS 0.722 (0.469 to 1.111); MTrPs 0.639 (0.396 to 1.032); ROM ER 1.008 (0.963 to 1.056); ROM IR 1.053 (0.988 to 1.122); ROM FF 1.011 (0.991 to 1.032); ROM Ext 1.082 (1.008 to 1.161); SF36 1.014 (0.971 to 1.059). The x-axis label is (unclear) with tick labels 0.5, 0.8, 1, 1.3, 1.5. A vertical dashed reference line is at 1. Markers: squares for Excellent Rate and diamonds for Total Efficacy, each with horizontal confidence-interval bars. Bottom annotation reads Anti effect on the left and Pro effect on the right. B) The image B showing a p value table with two columns. Column headers: Excellent Rate P Value and Total Efficacy P Value. Row values aligned to the same subgroups: ASES 0.348 and 0.948; VAS 0.051 and 0.139; MTrPs 0.008 and 0.067; ROM ER 0.009 and 0.724; ROM IR 0.009 and 0.114; ROM FF 0.159 and 0.270; ROM Ext 0.001 and 0.029; SF36 0.128 and 0.531. The detailed data points are as follows: - For the ASES subgroup, the excellent rate odds ratio was 1.015 with 95 percent confidence interval 0.983 to 1.049, the total efficacy odds ratio was 0.998 with 95 percent confidence interval 0.954 to 1.045, the excellent rate P value was 0.348 and the total efficacy P value was 0.948. - For the VAS subgroup, the excellent rate odds ratio was 0.727 with 95 percent confidence interval 0.528 to 1.002, the total efficacy odds ratio was 0.722 with 95 percent confidence interval 0.469 to 1.111, the excellent rate P value was 0.051 and the total efficacy P value was 0.139. - For the MTrPs subgroup, the excellent rate odds ratio was 0.607 with 95 percent confidence interval 0.420 to 0.877, the total efficacy odds ratio was 0.639 with 95 percent confidence interval 0.396 to 1.032, the excellent rate P value was 0.008 and the total efficacy P value was 0.067. - For the ROM ER subgroup, the excellent rate odds ratio was 1.047 with 95 percent confidence interval 1.012 to 1.084, the total efficacy odds ratio was 1.008 with 95 percent confidence interval 0.963 to 1.056, the excellent rate P value was 0.009 and the total efficacy P value was 0.724. - For the ROM IR subgroup, the excellent rate odds ratio was 1.062 with 95 percent confidence interval 1.015 to 1.112, the total efficacy odds ratio was 1.053 with 95 percent confidence interval 0.988 to 1.122, the excellent rate P value was 0.009 and the total efficacy P value was 0.114. - For the ROM FF subgroup, the excellent rate odds ratio was 1.010 with 95 percent confidence interval 0.996 to 1.024, the total efficacy odds ratio was 1.011 with 95 percent confidence interval 0.991 to 1.032, the excellent rate P value was 0.159 and the total efficacy P value was 0.270. - For the ROM Ext subgroup, the excellent rate odds ratio was 1.091 with 95 percent confidence interval 1.035 to 1.150, the total efficacy odds ratio was 1.082 with 95 percent confidence interval 1.008 to 1.161, the excellent rate P value was 0.001 and the total efficacy P value was 0.029. - For the SF36 subgroup, the excellent rate odds ratio was 1.024 with 95 percent confidence interval 0.993 to 1.056, the total efficacy odds ratio was 1.014 with 95 percent confidence interval 0.971 to 1.059, the excellent rate P value was 0.128 and the total efficacy P value was 0.531.

Forest plots displaying the odds ratios (ORs) with 95% CIs for the impact of individual clinical indicators on achieving an excellent efficacy rate and total efficacy. The vertical dashed line indicates a null effect (OR = 1).

Subgroup Analyses Reinforced These Findings

Subgroup analyses reinforced these findings, consistently favoring the combined therapy. Gender-stratified data confirmed significant improvements in both males and females for all functional and pain metrics (P < 0.05; Figure 10). Critically, the integrated protocol amplified the impact of clinical indicators: it enhanced the pain-modulating effects of MTrPs/VAS on excellent efficacy and augmented functional benefits from ASES/SF-36/ROM metrics, while uniquely strengthening the influence of anterior flexion (ROM-FF) on total efficacy—a phenomenon absents in the control group (Figure 11). No adverse events were reported, and treatment adherence exceeded 95% in both cohorts, underscoring the safety and feasibility of the combined intervention.

Figure 10.

Eight violin and box plot graphs of primary outcomes stratified by gender. The image A showing eight outcome plots titled ASES, MTrPs, VAS, SF36, ROM-ER, ROM-Ext, ROM-FF and ROM-IR, with a legend labeled Gender with categories Female and Male. Each plot combines a violin plot (probability density), a box plot (median, interquartile range, range) and individual data points. ASES: x-axis label Combination group and Control group (unit unclear). y-axis label ASES score (unit unclear). The Combination group and Control group each show Female and Male distributions; the Combination group distributions are centered higher than the Control group. MTrPs: x-axis label Combination group and Control group (unit unclear). y-axis label MTrPs (unit unclear). The Combination group distributions are centered lower than the Control group. VAS: x-axis label Combination group and Control group (unit unclear). y-axis label VAS score (unit unclear). The Combination group distributions are centered lower than the Control group. SF36: x-axis label Combination group and Control group (unit unclear). y-axis label SF36 score (unit unclear). The Combination group distributions are centered higher than the Control group. ROM-ER: x-axis label Combination group and Control group (unit unclear). y-axis label ROM-ER (unit unclear). The Combination group distributions are centered higher than the Control group. ROM-Ext: x-axis label Combination group and Control group (unit unclear). y-axis label ROM-Ext (unit unclear). The Combination group distributions are centered higher than the Control group. ROM-FF: x-axis label Combination group and Control group (unit unclear). y-axis label ROM-FF (unit unclear). The Combination group distributions are centered higher than the Control group. ROM-IR: x-axis label Combination group and Control group (unit unclear). y-axis label ROM-IR (unit unclear). The Combination group distributions are centered higher than the Control group. Across all eight plots, Female and Male are shown side by side within each group using distinct fill styles (unclear). No numeric tick values are legible for any y-axis, so exact medians, ranges and outliers are unclear.

Distribution of primary outcomes stratified by gender. Left panel shows box plots (median, IQR, range). Right panel displays violin plots with probability density.

Figure 11.

Two multi-plot line graphs of clinical indicators for excellent rate and total efficacy. The image A showing 8 small line graphs titled MTrPs, ASES, VAS, SF36, ROM-ER, ROM-Ext, ROM-FF, ROM-IR with y-axis label Excellent Rate (unit unclear) and two series labeled Control Group and Combination Group. MTrPs: x-axis (unit unclear) 2 to 4; y-axis 0.2 to 0.8; Control (2,0.30),(4,0.35); Combination (2,0.90),(4,0.50). ASES: x-axis 40 to 120; y-axis 0.2 to 0.8; Control (40,0.60),(120,0.20); Combination (40,0.55),(120,0.90). VAS: x-axis 1 to 6; y-axis 0.3 to 0.7; Control (1,0.35),(6,0.65); Combination (1,0.80),(6,0.45). SF36: x-axis 40 to 90; y-axis 0.1 to 0.6; Control (40,0.55),(90,0.12); Combination (40,0.55),(90,0.62). ROM-ER: x-axis 50 to 90; y-axis 0.3 to 0.8; Control (50,0.30),(90,0.30); Combination (50,0.45),(90,0.80). ROM-Ext: x-axis 40 to 70; y-axis 0.25 to 0.75; Control (40,0.38),(70,0.42); Combination (40,0.15),(70,0.85). ROM-FF: x-axis 125 to 200; y-axis 0.2 to 0.6; Control (125,0.32),(200,0.22); Combination (125,0.65),(200,0.50). ROM-IR: x-axis 40 to 80; y-axis 0.2 to 0.9; Control (40,0.35),(80,0.22); Combination (40,0.25),(80,0.85). The image B showing 8 small line graphs titled MTrPs, ASES, VAS, SF36, ROM-ER, ROM-Ext, ROM-FF, ROM-IR with y-axis label Total Efficacy (unit unclear) and two series labeled Control Group and Combination Group. MTrPs: x-axis 2 to 4; y-axis 0.6 to 1.0; Control (2,0.70),(4,0.70); Combination (2,1.00),(4,0.90). ASES: x-axis 40 to 120; y-axis 0.6 to 1.0; Control (40,0.92),(120,0.58); Combination (40,0.88),(120,1.00). VAS: x-axis 1 to 6; y-axis 0.4 to 1.0; Control (1,0.78),(6,0.40); Combination (1,1.00),(6,0.55). SF36: x-axis 40 to 90; y-axis 0.4 to 1.0; Control (40,0.90),(90,0.45); Combination (40,0.95),(90,0.88). ROM-ER: x-axis 50 to 90; y-axis 0.7 to 1.0; Control (50,0.66),(90,0.66); Combination (50,0.72),(90,1.00). ROM-Ext: x-axis 40 to 70; y-axis 0.6 to 1.0; Control (40,0.70),(70,0.78); Combination (40,0.55),(70,1.00). ROM-FF: x-axis 125 to 200; y-axis 0.4 to 1.0; Control (125,0.95),(200,0.45); Combination (125,0.70),(200,1.00). ROM-IR: x-axis 40 to 80; y-axis 0.3 to 1.0; Control (40,0.80),(80,0.32); Combination (40,0.75),(80,1.00).

Subgroup analysis demonstrating the differential influence of specific clinical indicators on (A) the excellent efficacy rate and (B) total efficiency between the combination therapy group and the control group.

Discussion

RCI manifests primarily manifests as shoulder pain and restricted range of motion, with early symptoms often developing insidiously as nocturnal or post-exertional pain. Without timely intervention, progression led to complications including muscular atrophy and glenohumeral instability, significantly impairing daily function. Current management focuses on three primary objectives: pain relief, adhesion release, and functional restoration. Although surgery rapidly improves mobility, its operative risks and prolonged rehabilitation,13 establish conservative approaches as valuable for mild-to-moderate cases. Rehabilitation training, particularly scapular stabilization exercises, enhances motor control, neuromuscular coordination, and strength,14 thereby improving function and promoting tissue repair. Systematic scapular training demonstrably increases active ROM and optimizes outcomes,15,16 yet its limitations include extended treatment duration and efficacy plateaus.16 Consequently, developing safer and more efficient integrated strategies is crucial for improving patients’ quality of life. This study suggests that integrating Canggui Tanxue acupuncture with SST yields higher overall efficacy compared to exercise monotherapy (P < 0.05), indicating enhanced tissue repair and superior therapeutic outcomes. Superior ASES scores (P < 0.001) confirmed significant functional improvement, likely attributable to synergistic mechanisms: SST corrects shoulder joint rhythm imbalances and enhances scapulothoracic stability, while acupuncture precisely targets pathological lesions through its unique acupuncture technique. This technique expands stimulation intensity while minimizing tissue damage. Collectively, these actions reduce inflammation and optimize function.15,17,18 Critically, the combination group achieved significantly lower VAS scores and fewer active MTrPs; P < 0.001), reflecting enhanced pain modulation. This analgesic effect may stem from acupuncture interrupting nociceptive signaling and suppressing central sensitization,19 potentially via its action at key shoulder acupoints that resolve qi-blood stasis and restore meridian flow.20,21 Significantly greater improvements in all ROM parameters (internal/external rotation, anterior flexion, extension; P < 0.001) further demonstrated superior mobility restoration through dual pathways:1) SST normalizes aberrant muscle tension and coordinating contraction, and 2) acupuncture releases myofascial/sarcomere spasms. Furthermore, as noted by recent literature, restoring ROM is critical not only for arm movement but also for overall body kinematics and postural stability.22 Finally, significantly elevated SF-36 scores (P < 0.001) confirmed substantive quality-of-life enhancement and improved long-term prognosis. Notably, unlike conventional electroacupuncture studies primarily focused on pain relief, this protocol adopts a “Heaven, Human, Earth” layered penetrating needling technique. By systematically penetrating the superficial fascia (Heaven), muscular layer (Human), and periosteal region (Earth), it effectively breaks down multi-layered fascial adhesions. This multi-depth release reduces tissue stiffness, which directly optimizes scapulothoracic kinematics and restores normal gleno-humeral rhythm. This approach may be the key mechanism behind the significant improvement in joint range of motion. Importantly, our real-world retrospective findings align closely with the results of recent high-quality randomized controlled trials (RCTs) investigating multimodal acupuncture therapies. For instance, a recent RCT23 evaluating Qihuang acupuncture combined with conventional rehabilitation for post-arthroscopic rotator cuff repair similarly targeted key acupoints such as Jianyu (LI15) and Jianqian (Extra). Consistent with our data, they demonstrated that the integrative approach yielded significantly greater reductions in VAS scores, superior improvements in ROM (particularly forward flexion and abduction), and a higher total effective rate (95.2% vs. 75.6%) compared to conventional therapy alone. While their trial focused on post-surgical rehabilitation and our cohort consisted of patients undergoing conservative management for mild-to-moderate RCI, the striking consistency in functional and analgesic outcomes provides compelling cross-validation. This comparison highlights that integrating specialized, multi-directional acupuncture techniques with structured physical rehabilitation represents a robust and broadly applicable strategy across the continuum of rotator cuff pathology. Additionally, future research should further validate the differential contributions of various needling techniques (eg., electroacupuncture frequency, penetration angle) to functional recovery.

Key strengths of this study include its novel integrated approach, strategically designed to address limitations of conventional therapies by providing an optimized alternative for RCI pain and dysfunction. The multi-dimensional assessment framework systematically validated treatment effectiveness across pain relief, functional recovery, and overall efficacy domains.

Limitations include inherent experimental design constraints. First, the lack of patient and practitioner blinding may introduce bias, particularly in patient-reported outcome measures (PROMs) such as VAS and ASES. Second, treatment standardization may be affected by individual practitioner variance during acupuncture and SST. Third, due to the retrospective nature, unmeasured confounding factors (eg., patient belief in acupuncture, adherence to home exercises, and lifestyle factors) could not be fully controlled. Fourth, the study may have limited power from a sample size of 160, affecting generalizability, and a short-term follow-up (6 weeks), precluding evaluation of long-term outcomes. Future research should prioritize long-term follow-up studies, conduct comparative trials with different acupuncture protocols (eg., electroacupuncture), and focus on patient phenotyping to identify subgroups that optimize treatment outcomes.

Conclusions

This real-world cohort study demonstrates that the integration of Canggui Tanxue acupuncture with SST provides statistically and clinically superior outcomes compared to SST monotherapy, evidenced by: 1) Functional restoration (28.75% absolute increase in excellent efficacy rates, ASES Δ=11.89 points exceeding MCID); 2) Pain modulation (VAS reduction Δ1.43 points, NNT=3.48 for excellent pain relief); 3) Biomechanical improvement (ROM-extension increased by 9.74°—critical for overhead activities). The observed synergy likely stems from concurrent targeting of scapulothoracic dyskinesis (via SST) and peripheral nociceptive sensitization (via Canggui Tanxue’s multi-directional needling). These findings suggest that the combined protocol may be particularly beneficial for patients with: 1) Baseline ROM-extension ≤50° (OR=3.21 from nomogram); 2) High pain catastrophizing scores (indirect evidence from SF-36 subanalysis). The implementation of this multimodal approach offers a safe and highly effective conservative strategy for enhancing functional recovery in RCI management.

Funding Statement

There is no funding to report.

Data Sharing Statement

The original contributions presented in the study are included in the article. Further inquiries can be directed to the corresponding author(s).

Ethics Statement

The study was conducted in accordance with the Decla-ration of Helsinki and was approved by the Institutional Review Board of Hainan General Hospital, Hainan Medical University (Approval No. YL-2025-03).

Informed Consent Statement

The need for written informed consent was waived by the IRB be-cause: 1) Data were anonymized prior to analysis; 2) All treatments represented standard clinical practice; 3) No additional biospecimen/procedure was required.

Publication Consent Statement

We confirm that all images and materials in this manuscript are approved for publication, and all authors have read and approved the final version of the manuscript to be published.

Author Contributions

All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.

Disclosure

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

References

  • 1.Zhao W, Yang J, Kang Y, et al. Animal models of rotator cuff injury and repair: a systematic review. Tissue Eng Part B Rev. 2022;28(6):1258–15. doi: 10.1089/ten.teb.2022.0034 [DOI] [PubMed] [Google Scholar]
  • 2.Xu P. Effects of ultrasound-guided platelet-rich plasma combined with sodium hyaluronate on shoulder function recovery, pain degree and mental health of patients with rotator cuff injury. Biotechnol Genet Eng Rev. 2024;40(1):217–236. [DOI] [PubMed] [Google Scholar]
  • 3.Feuerriegel GC, Fritz B, Marth AA, Sommer S, Wieser K, Sutter R. Assessment of the rotator cuff muscles: state-of-the-art MRI and clinical implications. Radiology. 2025;315(2):e242131. doi: 10.1148/radiol.242131 [DOI] [PubMed] [Google Scholar]
  • 4.Silveira A, Luk J, Tan M, et al. move it or lose it? The effect of early active movement on clinical outcomes following rotator cuff repair: a systematic review with meta-analysis. J Orthopaed Sports Phys Ther. 2021;51(7):331–344. doi: 10.2519/jospt.2021.9634 [DOI] [PubMed] [Google Scholar]
  • 5.Powell JK, Lewis JS. Rotator cuff-related shoulder pain: is it time to reframe the advice, “you need to strengthen your shoulder”? J Orthopaed Sports Phys Ther. 2021;51(4):156–158. doi: 10.2519/jospt.2021.10199 [DOI] [PubMed] [Google Scholar]
  • 6.Li C, Qi X, Wang F, Wang J. Clinical efficacy of acupuncture with Canggui Tanxue technique on huantiao point for treating sciatica caused by lumbar disc herniation. Alternative Therap Health Med. 2023;29(7):376–381. [PubMed] [Google Scholar]
  • 7.Xu CC, Li XH, Li JL. Comparative study on curative effect and recurrence rate of chronic scapulohumeral periarthritis treated with different acupuncture techniques. Zhen Ci Yan Jiu. 2024;49(2):164–170. doi: 10.13702/j.1000-0607.20221004 [DOI] [PubMed] [Google Scholar]
  • 8.Hill BW, Joyce CD, Singh A, Guttman MJ, Williams GR, Namdari S. Patients with mild osteoarthritis are less likely to achieve a clinically important improvement in pain or function after anatomic total shoulder arthroplasty. Clin Orthopaedics Related Res. 2023;481(8):1464–1470. doi: 10.1097/CORR.0000000000002609 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Goudman L, Pilitsis JG, Billet B, et al. The level of agreement between the numerical rating scale and visual analogue scale for assessing pain intensity in adults with chronic pain. Anaesthesia. 2024;79(2):128–138. doi: 10.1111/anae.16151 [DOI] [PubMed] [Google Scholar]
  • 10.Kobylarz MD, Klich S, Sánchez-Jorge S, Buffet-García J, Ortega-Santiago R, Valera-Calero JA. Shear-Wave elastography supports that muscle stiffness should NOT be considered a criterion to determine the presence of myofascial trigger points in the infraspinatus muscle. Am J Phys Med Rehabil. 2025;104:890–895. doi: 10.1097/PHM.0000000000002721 [DOI] [PubMed] [Google Scholar]
  • 11.Hanks J, Myers B. Validity, reliability, and efficiency of a standard goniometer, medical inclinometer, and builder’s inclinometer. Int J Sports Phys Ther. 2023;18(4):989–996. doi: 10.26603/001c.83944 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Moosmayer S, Lund G, Seljom US, et al. Fifteen-year results of a comparative analysis of tendon repair versus physiotherapy for small-to-medium-sized rotator cuff tears: a concise follow-up of previous reports. J Bone Hoint Surg Am. 2024;106(19):1785–1796. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Bedi A, Bishop J, Keener J, et al. Rotator cuff tears. Nat Rev Dis Primers. 2024;10(1):8. doi: 10.1038/s41572-024-00492-3 [DOI] [PubMed] [Google Scholar]
  • 14.Liaghat B, Skou ST, Søndergaard J, Boyle E, Søgaard K, Juul-Kristensen B. Short-term effectiveness of high-load compared with low-load strengthening exercise on self-reported function in patients with hypermobile shoulders: a randomised controlled trial. Br J Sports Med. 2022;56(22):1269–1276. doi: 10.1136/bjsports-2021-105223 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Sun JN, Zheng QY, Wang RS, Ma YR, Chen P. An additional rehabilitation program to improve postoperative outcomes in patients with rotator cuff tear and scapular dyskinesis: a propensity score-matched study. BMC Musculoskelet Disorders. 2025;26(1):338. doi: 10.1186/s12891-025-08596-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Yuksel E, Yesilyaprak SS. Scapular stabilization exercise training improves treatment effectiveness on shoulder pain, scapular dyskinesis, muscle strength, and function in patients with subacromial pain syndrome: a randomized controlled trial. J Bodywork Movement Therap. 2024;37:101–108. doi: 10.1016/j.jbmt.2023.11.005 [DOI] [PubMed] [Google Scholar]
  • 17.Manceron A, Jawa A, Mantovani M, Werthel JD. Involvement of the scapulothoracic articulation after well-functioning reverse total shoulder arthroplasty. J Shoulder Elbow Surg. 2025;34:2258–2268. doi: 10.1016/j.jse.2024.12.018 [DOI] [PubMed] [Google Scholar]
  • 18.Xie J, Li J, Sun Q, Jiang J. Multidimensional evaluation of the clinical efficacy and potential mechanisms of acupuncture combined with rehabilitation training in the treatment of stroke: a study based on multiple evaluation indicators. Front Neurol. 2025;16:1573073. doi: 10.3389/fneur.2025.1573073 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Liu Y, Jin F, Zhou L, et al. Platelet-derived growth factor receptor-α induces contraction knots and inflammatory pain-like behavior in a rat model of myofascial trigger points. Anesthesiology. 2024;141(5):929–945. doi: 10.1097/ALN.0000000000005167 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Xiong J, Zhou X, Luo X, et al. Acupuncture therapy on myofascial pain syndrome: a systematic review and meta-analysis. Front Neurol. 2024;15:1374542. doi: 10.3389/fneur.2024.1374542 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Liu S. Chronic supraspinatus tendonitis pain: an integrative approach for treatment with cross-fiber massage, electroacupuncture, far-infrared heat, and photobiomodulation. Med Acupuncture. 2022;34(4):251–255. doi: 10.1089/acu.2022.0041 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Ata AM, Tuncer B, Kara O, Başkan B. The relationship between kinesiophobia, balance, and upper extremity functions in patients with painful shoulder pathology. Pm r. 2024;16(10):1088–1094. doi: 10.1002/pmrj.13145 [DOI] [PubMed] [Google Scholar]
  • 23.Sun Q, Xu Z, Yu J, et al. [Qihuang acupuncture therapy for mid-term postoperative pain after arthroscopic rotator cuff repair: a randomized controlled trial]. Zhongguo Zhen Jiu. 2026;46(3):341–346. doi: 10.13703/j.0255-2930.20250217-0006 Dutch [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

The original contributions presented in the study are included in the article. Further inquiries can be directed to the corresponding author(s).


Articles from Journal of Pain Research are provided here courtesy of Dove Press

RESOURCES